Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

207.92
+2.351.14%
Volume:835.76K
Turnover:173.02M
Market Cap:44.56B
PE:-23.31
High:208.89
Open:205.50
Low:202.54
Close:205.57
52wk High:224.31
52wk Low:37.88
Shares:214.34M
Float Shares:184.00M
Volume Ratio:0.41
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.10
PE(LYR):-34.94

Loading ...

MEDIA-Cancer drugmaker Revolution Medicines says sale not a priority - FT

Reuters
·
Jun 21

Revolution Medicines COO Margaret Horn disposes of 93,575 common shares worth $14.99 million

Reuters
·
Jun 18

Revolution Medicines COO Margaret Horn disposes of 10,000 common shares worth $1.48 million

Reuters
·
Jun 16

Revolution Medicines Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Jun 11

Movement Alert|Revolution Medicines Falls 5.21% in Regular Trading, Trading at $142.305

Market Focus
·
Jun 10

BUZZ-Tango Therapeutics rises premarket after upsized $600 mln equity raise

Reuters
·
Jun 10

Revolution Medicines Earns Buy Rating on Strong PDAC Execution, First-Mover Advantage, and Daraxonrasib-Driven Growth Potential

TIPRANKS
·
Jun 09

BUZZ-IDEAYA Biosciences drops on $300 mln equity raise

Reuters
·
Jun 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dexcom (DXCM), Revolution Medicines (RVMD) and Incyte (INCY)

TIPRANKS
·
Jun 09

Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment -- Barrons.com

Dow Jones
·
Jun 09

RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position

TIPRANKS
·
Jun 08

Why Revolution Medicines (RVMD) Is Down 8.8% After Phase 3 Daraxonrasib Pancreatic Cancer Survival Data Release And What's Next

Simply Wall St.
·
Jun 08

Tango Therapeutics' pancreatic cancer drug combo shows promise in study

Reuters
·
Jun 08

Bernstein Remains a Hold on Revolution Medicines (RVMD)

TIPRANKS
·
Jun 08

Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says

MT Newswires Live
·
Jun 02

Movement Alert|Revolution Medicines Falls 5.13% in Regular Trading, Profit-Taking After ASCO Pancreatic Cancer Data Rally

Market Focus
·
Jun 02

Analyst Reiterates Buy on Revolution Medicines Amid Strong ASCO Feedback and Optimism for RAS-Targeted Solid Tumor Portfolio

TIPRANKS
·
Jun 02

Revolution Medicines price target raised to $182 from $165 at RBC Capital

TIPRANKS
·
Jun 02

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Reuters
·
Jun 02

Movement Alert|Revolution Medicines Rises 5.11% in Regular Trading, ASCO Phase 3 Pancreatic Cancer Data Continues to Boost Stock

Market Focus
·
Jun 02